Skip to main content

Table 1 Characteristics of the subjects

From: Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

Characteristics

Switching group

(n = 32)

Continuing group

(n = 24)

P value

Age (years), median (range)

72 (47–81)

68 (45–80)

0.152

Height (cm)

151.3 ± 4.0

152.9 ± 5.0

0.318

Weight (kg)

49.6 ± 6.1

48.3 ± 6.0

0.425

Body mass index (kg/m2)

21.7 ± 2.6

20.7 ± 2.3

0.208

Time since menopause (year)

19.2 ± 7.8

14.6 ± 9.3

0.097

Number of cases with surgical menopause, n (%)

9 (28)

5 (21)

0.756

Femoral neck BMD (g/cm2)

0.517 ± 0.064

0.553 ± 0.077

0.094

Femoral neck BMD (T-score)

−2.2 ± 0.3

−2.0 ± 0.3

0.076

Lumbar BMD (g/cm2)

0.714 ± 0.096

0.744 ± 0.083

0.175

Lumbar BMD (T-score)

−1.9 ± 0.4

−1.7 ± 0.5

0.155

Serum NTX (nmol BCE/L)

12.36 ± 3.62

13.35 ± 6.87

0.984

Serum BAP (U/L)

9.63 ± 3.13

9.10 ± 2.57

0.620

  1. Mean ± Standard Error (SE), unless otherwise noted
  2. BMD bone mineral density, NTX N-terminal telopeptide, BAP bone-specific alkaline phosphatase